Tune in to hear latest updates from ASCO and EHA in myeloma! @chadinabhan is so naturally curious and able to draw out the interesting storylines!.

RT @chadinabhan: Tomorrow on #HealthcareUnfiltered, I host ⁦@bdermanmd⁩ of ⁦@UCCancerCenter⁩ to discuss myeloma updates from ⁦@ASCO⁩ #ASCO2….

RT @Transplant_Doc: Sequential BCMA CAR-T Cell Therapy (cilta-cel in patients relapsing after ide-cel) in RRMM. N=10, VGPR: 100%, MRD-ve: 6….

*correction - these are in vivo- no gvhd. Should read to reduce immunogenicity.

- What will happen with toxicity as dose escalates? We already see grade 3 CRS (though unclear if toci used early to mitigate) .- Will in-vivo CAR T allow for better treatment of EMD? .- Will need to see if risk of T-cell lymphomas are different than typical. CAR T .- What is the.

4 patients have been treated thus far. ‼️CRS grade 3 occurred in 3 of the 4 patients (!). ICANS in 1 patient with CNS disease. All responded to steroids. 👍 All 4 patients have had a response. Including one with EMD. 😎2 s/CRs and the other two had MRD negativity (just hadn't

In-vivo CAR Ts for myeloma are going to come fast and furious. These products are engineering marvels. ESO-T01 (EsoBiotec) is an anti-BCMA in-vivo CAR T that: .1) Delivers the CAR transgene to endogenous T-cells, reprogramming them to CAR T cells in situ .2) Overexpress CD47 to

RT @TheLancetHaem: 📢Final BELLINI results at 45.6 months follow-up show no overall survival benefit of venetoclax in the general relapsed o….

RT @majorajay: No more REMS for FDA-approved CAR-T products! Also, labeling updated for only 2 weeks in proximity to CAR center and 2 weeks….

RT @VincentRK: Just out: Guidelines for testing and reporting cytogenetic results in myeloma @BloodCancerJnl⁩ #OpenAccess Bookmark!. Allows….

RT @theMMRF: Join us in ONE week for an MMRF Patient Webinar for the latest updates in #myeloma treatment, straight from #ASCO25 and #EHA20….

RT @YiLinMDPhD: @VincentRK @MayoMyeloma While many #CART centers are proficient in managing CRS & ICANS, we are all learning how best to ev….

One other thing I want to highlight here. This was an academic investigator initiated trial performed in the United States with over 300 patients from only seven institutions. The patient demographics were diverse. This is no small feat and the investigators should be.

A lot of studies with K-based quad induction being presented. From the IsKia trial (Isa-KRd vs KRd), with ongoing consolidation post-transplant, we see smaller differences in MRD negativity as time goes on with addition of Isa. Except for those with 2+ high-risk abnormalities.

On to efficacy: .100% ORR in the BCMA/GPRC5D-exposed patients! Can't beat that - and these are DEEP responses. Still with 55% ORR in all BCMA/GPRC5D-exposed patients. As for PFS, 95% 12-month PFS at the RP2D in the unexposed group! Longest responses at 20 months thus far with

Grade 3+ infections seem lower than prior studies with other BsAbs. While taste/skin/nail changes are seen, the severity seems to be lower. Perhaps most important - we don't see significant weight loss (which is a problem with talquetamab)

About a quarter of patients were exposed to both BCMA/GPRC5D-targeting agents.

Dosing is very convenient - half-life allows for q4 week dosing. Major benefit!.The RP2D is 100 mg q4weeks SQ

JNJ-5322: BCMAxGPRC5DxCD3 Trispecific.- Idea is that you may get less off-tumor toxicity by dual targeting of BCMA and GPRC5D

Potent regimen. Responses deepening over time. Follow-up is quite immature. One death on study. A few discontinued due to adverse events. I'm sure we will be seeing much more BsAb upfront.